The challenges in controlling the HIV epidemic in Angola: Experience of Nossa Senhora da Paz Hospital, Cubal

Authors

Keywords:

HIV infection in Angola, HIV treatment failure, opportunistic infections

Abstract

Nossa Senhora da Paz Hospital (HNSP) has 11 years of experience in HIV management. Treatment failures with second-line antiretroviral drugs (ART) and an increase in opportunistic infections represent a challenge for the future of this disease in Angola. It was done with the aim of determining the characteristics of HIV patients treated at HNSP from 01 January 2015 to 31 August 2016, as well as the characteristics of patients on ART from 01 January 2010 to 30 September 2016. To this end, a retrospective analysis of the patients enrolled in the DREAM Programme was performed, recording their age, gender, CD4 levels and stage at diagnosis, initiation of ART and their evolution. During the 20 months, 3,089 HIV tests were performed, of which 138 were positive, indicating a prevalence of 4.5%. From 1 January 2010 to date, 906 patients have received ART, of which 66.9% are women. Currently, the DREAM programme is monitoring 606 patients, of whom 505 are on ART. Of the patients on ART, 17 are on second-line ART and 7 have confirmed resistance to ART. Co-infection with Tuberculosis is 24.3%. From 1 January 2015 to 30 September 2016 128 new cases were incorporated, 11.7% died within the first 30 days of diagnosis and 6 of these have CD4 levels less than 50 with an incidence of cryptococcal meningitis of 33.3%. It is necessary to design strategies for the target population in the early diagnosis of HIV in order to make diagnosis at the early stage, reducing mortality. A verified problem is the failure of second-line ART. The incorporation of new therapeutic families is an imperative need along with addressing opportunistic infections and incorporating viral load to ensure quality HIV program in Angola.

References

Asamblea General de las Naciones Unidas. 2011.

GLOBAL AIDS UPDATE. UNAIDS – 2016.

Asamblea Naciones Unidas. Junio 2016.

Dados do Ministério da Saúde, Angola. 1 Dezembro. 2016. Informe Provincia Benguela.

Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008; 22:1897-908.

World Health Organisation. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach - 2nd ed. WHO Guidel2016:480.

Guichet E, Aghokeng AF, Serrano L, Bado G, Toure-Kane C, Eymard-Duvernay S, et al. High viral load and multidrug resistance due to late switch to second-line regimens could be a major obstacle to reach the 90-90-90 UNAIDS objectives in sub-Saharan Africa. AIDS Res Hum Retroviruses 2016; 32:1–13.

Konou AA, Salou M, Vidal N, Kodah P, Kombate D, Kpanla P, et al.Virological outcome among HIV-1 infected patients on first-line antiretroviral treatment in semi-rural HIV clinics in Togo. AIDS Res Ther 2015; 12:38.

Boullé C, Guichet E, Kouanfack C, Aghokeng A, Onambany B, Ikaka CM, et al. Virologic failure and HIV drug resistance in rural Cameroon with regard to the UNAIDS 90-90-90 treatment targets. Open Forum Infect Dis 2016:ofw233.

Muri L, Gamell A, Ntamatungiro AJ, Glass TR, Luwanda LB, Battegay M, et al. Development of HIV drug resistance and therapeutic failure in children and adolescents in rural tanzania – an emerging public health concern. AIDS 2017; 31:61-70.

Konou AA, Dagnra AY, Vidal N, Salou M, Adam Z, Singo-Tokofai A, et al.Alarming rates of virological failure and drug resistance in patients on long-term antiretroviral treatment in routine HIV clinics in Togo. AIDS 2015; 29:2527–30.

Boender TS, Kityo CM, Boerma RS, Hamers RL, Ondoa P, Wellington M, et al. Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa. J AntimicrobChemother 2016; 71:2918–2927.

Dube NM, Tint KS, Summers RS. Early warning indicators for HIV drug resistance in adults in South Africa at 2 pilot sites, 2008-2010. Clin Infect Dis 2014; 58:1607–1614.

Rossouw TM. Monitoring Early Warning Indicators for HIV Drug Resistance in South Africa: Challenges and Opportunities.Clin Infect Dis 2014; 58:1615–1617.

Ta IL, Smith BR, von Geldern G, et al. HIV-associated opportunistic infections of the CNS. Lancet Neurol 2012; 11: 605-17.

Jarvis JN, Meintjes G, William A et al. Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. BMC Infect Dis 2010;10:67.

Sloan DJ, Parris V. Cryptococcal meningitis: epidemiology and therapeutic options. ClinEpidemiol 2014; 6: 169-82.

Jarvis JN, Lawn SD, Vogt M, et al. Screening for cryptococcalantigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 2009; 48:856–62.

Jarvis JN, Govender N, Chiller T, et al. Cryptococcal antigen screening and preemptivetherapy in patients initiating antiretroviral therapy in resource-limited settings: a proposed algorithm for clinical implementation. J Int Assoc Physicians AIDS Care (Chic) 2012; 11:374–9.

Published

2017-12-12

How to Cite

Pessela, A., Olivas, E. G., Mateus, R. M. ., Samba, F., Vicente, & Nicasio, M. M. . (2017). The challenges in controlling the HIV epidemic in Angola: Experience of Nossa Senhora da Paz Hospital, Cubal. Revista Sol Nascente, 6(2), 03–17. Retrieved from https://revista.ispsn.org/index.php/rsn/article/view/61